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Many neurological and psychiatric disorders affect
the cerebral cortex, and a clearer understanding of
the molecular processes underlying human corti-
cogenesis will provide greater insight into such pa-
thologies. To date, knowledge of gene expression
changes accompanying corticogenesis is largely
based onmurine data. Here we present a searchable,
comprehensive, temporal gene expression data set
encompassing cerebral cortical development from
human embryonic stem cells (hESCs). Using a modi-
fied differentiation protocol that yields neurons sug-
gestive of prefrontal cortex, we identified sets of
genes and long noncoding RNAs that significantly
change during corticogenesis and those enriched
for disease-associations. Numerous alternatively
spliced genes with varying temporal patterns of
expression are revealed, including TGIF1, involved
in holoprosencephaly, and MARK1, involved in
autism. We have created a database (http://
cortecon.neuralsci.org/) that provides online,
query-based access to changes in RNA expression
and alternatively spliced transcripts during human
cortical development.
INTRODUCTION
The cerebral cortex is responsible for processing sensory input,
encoding memories, coordinating motor movements, thought,
and planning complex behaviors. Accomplishing these sophisti-
cated tasks involves billions of intricately connected neurons in
highly ordered layers and columns (Jones and Rakic, 2010).
Cortical development involves a precisely orchestrated program
of progenitor cell expansion, neuron differentiation, neuronal
migration, and circuit formation to create its highly organized
cytoarchitecture.Knowledge of global gene expression patterns during corti-
cogenesis has been largely based on data obtained in mouse
systems (Belgard et al., 2011; Dougherty and Geschwind,
2005). Recent studies using RNA sequencing (RNA-seq) have
uncovered novel coding, noncoding, and alternatively spliced
transcripts expressed specifically in each cortical layer and
at different developmental stages, providing a more compre-
hensive view of murine cortical development (Belgard et al.,
2011; Hubbard et al., 2013). There are notable differences
between mouse and human cortices, the most obvious being
a 1,000-fold difference in size, and humans have a significantly
larger and more complex cortex. This elaboration is reflected
in the elongated gestation: cortical neurogenesis is approxi-
mately 70 days in humans (Caviness et al., 1995) but only
7–8 days in mice (Takahashi et al., 1996). Differences between
mouse and human cortical development are also evident at
the molecular level, with distinctly different gene expression
profiles in the cortical germinal zones of mouse and human
(Fietz et al., 2012); 30% of the layer-specific cortical markers
are differentially expressed between mouse and human (Zeng
et al., 2012).
Most human cerebral cortex transcriptome studies have been
carried out on postmortem tissue using microarray techniques
(Hawrylycz et al., 2012; Kang et al., 2011). Given the differences
in mRNA expression, splicing, and editing observed throughout
cerebral cortical development (Dillman et al., 2013) and the
limitations of microarray technology, deep sequencing tech-
nology is needed to fully characterize the transcriptomic
changes during corticogenesis. Differentiation of human embry-
onic stem cells (hESCs) into cortical progeny has been demon-
strated to be a viable model of human cortical development
(Gaspard et al., 2008; Johnson et al., 2007; Kim et al., 2011;
Shi et al., 2012). In this study, we used an adapted protocol to
differentiate hESCs into cortical neurons over 77 days; per-
formed RNA-seq during the process to generate a comprehen-
sive transcriptome database encompassing human in vitro
corticogenesis; and conducted analyses for KEGG pathways,
gene ontology (GO) categories, disease associations, and
alternative splicing. We provide the database and analytical
results as a resource released in raw data format as well as aNeuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc. 51
Figure 1. Establishing a Workflow for In Vitro Corticogenesis
(A) Schematic of cortical differentiation protocol, based on dual SMAD-inhibition (LDN = LDN193189; SB = SB431542; KSR = ‘‘Knockout Serum Replacement
media’’; N2 = DMEMF12 with N2 supplement; N2/N27 is DMEMF12 supplemented with N2 and B27) with each media represented by a different color. The
collection times used for RNA-seq profiling are printed above the timeline. Shown below the schematic are phase images of cultures at days 0, 12, and 77 of the
protocol.
(B) Real-time qPCR to verify differentiation of hESC to anterior neural progenitors. Prosencephalic marker, PAX6; Telencephalic marker, FOXG1; dorsal telen-
cephalon marker EMX2; ventral telencephalic markers, NKX2-1, DLX1. No signal was observed for either of the posterior markers. All error bars are SD.
(C) Immunocytochemistry of known neural differentiation and cortical layer markers to establish validity of the protocol. Pluripotency markers: NANOG, POU5F1
(OCT4; day 0). Neural induction markers: NES (day 7), MKI67 (day 0), OTX2 (day 12), and PAX6 (day 12); ADRA2A (L6; day 19), DRD5 (L5; day 19), GRM4 (L4; day
35), and POU3F2 (L2–L4; previously BRN2; day 35).
(legend continued on next page)
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org/—with interactive access to the computational analyses.
RESULTS
Simulating Human Cortical Development In Vitro
We adapted previously published differentiation protocols
(Chambers et al., 2009; Gaspard et al., 2008) to simulate cortical
development in 2D adherent cultures. hESCs were grown and
neural induction was initiated using the dual SMAD-inhibition
protocol (Chambers et al., 2009). To ensure a dorsal telence-
phalic fate, the sonic hedgehog antagonist cyclopamine was
added on day 3 of neural induction (Gaspard et al., 2008).
Throughout the entire subsequent period of cortical differentia-
tion, cultures were maintained in N2B27 medium (Gaspard
et al., 2008) supplemented with FGF-2 (Figure 1A). To verify
that this protocol was in good agreement with previously pub-
lished results (Shi et al., 2012), we performed quantitative real-
time PCR analysis during the first 12 days of the differentiation,
focusing on several known markers of neural specification (Fig-
ure 1B). This revealed a steady increase in the prosencephalic
marker PAX6 (Zhang et al., 2010) and increased expression
of the telencephalic marker FOXG1, indicating acquisition of a
telencephalic fate (He´bert and Fishell, 2008). EMX2 (Cecchi,
2002), a dorsal telencephalon marker, steadily increased over
this period, indicating cerebral cortical fate acquisition (Fig-
ure 1B). Notably, no expression of the ventral telencephalic
markers NKX2-1 and DLX1 (He´bert and Fishell, 2008) was
detected.
The cell phenotypes produced in the cultures were identified
using immunocytochemistry. Expression of the pluripotency
markers NANOGandPOU5F1 (OCT4) was high in the undifferen-
tiated hESCs, and both proteins rapidly decreased after initiation
of neural differentiation as expected (data not shown). Upon neu-
ral differentiation, the neural progenitor cell marker Nestin (NES)
was induced, concomitant with high levels of the proliferative
marker MKI67. Strong expression of PAX6 and OTX2 confirmed
that a dorsal, cortical specification had occurred (Figure 1C).
Neurons destined for different cortical layers are formed in a
set sequence. To assess whether the appropriate cortical cell
layers were forming during the differentiation protocol, we
carried out immunocytochemistry for markers selected from a
recent study identifying several adult human layer-specific
cortical markers by in situ hybridization in postmortem human
brain (Zeng et al., 2012). Expression of adrenoreceptor alpha
2A (ADRA2A; layer VI) and dopamine receptor D5 (DRD5;
layer V) confirmed deep layer formation, and expression of gluta-
mate receptor, metabotropic 4 (GRM4; layer IV) and POU class 3
homeobox 2 (POU3F2; layer IV-II) indicated the presence of mid
and upper layer cells. Together, these data show the 77 day pro-
tocol recapitulates human cortical development in vitro, encom-(D) Pearson correlations of Cortecon replicates.
(E) Comparative analysis of RNA-seq data with BrainSpan Atlas of the Develo
microdissected human fetal brain regions. Human sample ages range from 9 po
gross brain regions. Due to lack of data pertaining to the whole cortex in Brainspa
closely correlated with other cortical regions. Ventrolateral Prefrontal Cortex (VF
(TH); cerebellum (CB). See also Figures S1 and S2.passing all stages from pluripotency to upper layer neuron
generation.
RNA-Seq Measures of In Vitro Human Cortical
Development
We used RNA-seq to determine gene expression changes
occurring during the span of corticogenesis. Analysis was car-
ried out using R (Team, 2012) and packages available through
Bioconductor (Gentleman et al., 2004). Data were derived from
samples generated in two separate cortical differentiation exper-
iments: a full differentiation (day 0, 7, 19, 33, 49, 63, and 77; two
samples designated A and B) and a shorter differentiation (day 0,
7, 12, 19, and 26; two samples designated C and D). To verify
that these two differentiations produced similar transcriptional
profiles, we determined the Pearson product-moment correla-
tion coefficient (Pearson’s r) for all combinations of biological
and experimental replicates (Figure 1D; Figure S1A available
online) that showed a strong correlation between expression
profiles generated on the same day of differentiation regardless
of experimental origin, indicating strong reproducibility.
The cortical RNA-seq datasets were compared to data in the
BrainSpan Atlas of the Developing Human Brain (Miller et al.,
2014) (http://brainspan.org/), which contains transcriptome
profiles generated by RNaseq from macrodissected and laser-
microdissected human fetal brain regions from multiple time
points during development (9, 12, 13, 17, 21, 24, 26, 56, and
92 postconception weeks). This analysis demonstrated the
genes expressed by in vitro generated cortical cells correlated
best with human fetal cerebral cortex transcriptomic profiles as
compared to other brain regions (Figure 1E). Notably, the anal-
ysis indicates the cells generated by this protocol most closely
resemble medial prefrontal cortex (Figure S1B) while showing
the least similarity to primary somatosensory and auditory
regions.
Global Temporal Transcriptome Analysis of In Vitro
Corticogenesis
EdgeR and DESeq2 (Anders et al., 2013) were used to gain
insight into the dynamic changes in the transcriptome during
the cortical differentiation period. A total of 14,065 RNAs
exhibited significant changes during the time course (adjusted
p value <0.05 and a 2-fold change), common to both EdgeR
and DESeq2, out of 31,041 expressed RNAs. A total of 1,729
of these were long intergenic, noncoding RNAs (lincRNAs) (Fig-
ure 2A; Table S1). To better understand the gene expression
changes occurring, we utilized the GOseq package (Young
et al., 2010) to determined enriched GO categories. CateGOrizer
(Zhi-Liang et al., 2008), which parses GO analysis into a more
user-friendly format, was used to count the number of enriched
GOcategories falling under a hand-annotated list of the develop-
mental categories (Table S2). As expected, the major group ofping Human Brain of transcriptome profiles from macrodissected and laser-
stconceptual weeks to 1 year old. Shown are the Spearman correlations with
n, VFC was used to represent cortex in the brain-wide comparison because it
C); hippocampus (HIP); striatum (STR); amygdaloid complex (AMY); thalamus
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Figure 2. Global View of Temporal Expression Profiles during In Vitro Corticogenesis
RNA-seq was used to determine the transcriptome at frequent intervals during in vitro corticogenesis.
(A) Distribution of significantly changing transcripts.
(B) Significantly enriched developmentally related GO categories aggregated into more comprehensive terms.
(C) Significantly enriched KEGG pathways in the global gene set and their distribution among six categories. Nervous-system-related pathways are highlighted
and displayed with calculated z scores.
(D) Significantly enriched diseases categorized as being a ‘‘nervous system disorders,’’ brain-related disease, a type of ‘‘cancer,’’ ‘‘other disorders,’’ or a
combination of these categories. See also Tables S1, S2, S3, and S4.
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‘‘Nervous System Development’’ category, providing confi-
dence in the differentiation and analysis, and smaller groups
aligned with categories describing the development of a variety
of other anatomical systems (Figure 2B; Table S2).
Key signaling pathways in the global RNA-seq data were eluci-
dated using the Signaling Pathway Impact Analysis (SPIA) pack-
age (Tarca et al., 2009). SPIA utilizes the curated KEGG pathway
repository to help determine the relative representation of spe-
cific pathways in expression data. Significantly enriched KEGG
signaling pathways included several main categories: ‘‘Cell Pro-
cesses,’’ ‘‘Cancer,’’ ‘‘Canonical Signaling,’’ ‘‘Nervous System,’’
and ‘‘Immune and Infectious Disease’’ (Figure 2C; Table S3).54 Neuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc.Many pathways implicated in normal neuronal development
were highlighted by SPIA. For example, genes falling under the
neuroactive-ligand receptor interaction-signaling pathway regis-
ter as enriched. The glutamatergic synapse-signaling pathway is
also enriched, which is encouraging, as the majority of endo-
genous cortical neurons are glutamatergic. In addition, several
other synaptic pathways are enriched, such as the GABAergic,
serotonergic, and dopaminergic pathways, signifying that a
multitude of genes required for neuronal function increase
expression over the time course. For example, neurotrophic
factors (e.g., BDNF, Neurotrophin 3) play key roles in neuronal
maturation, synaptogenesis, and cortical development (Zweifel
et al., 2005) and show expected dynamic changes throughout
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tion, such as SLC17A6 (Kaneko and Fujiyama, 2002), increase
during the later stages as expected (Figure S2).
Genes showing differential expression during in vitro cortico-
genesis were analyzed using the DISEASES database (http://
diseases.jensenlab.org/), which ranks disease-gene associa-
tions mined from the literature using Disease Ontology terms.
Using GOseq along with the DISEASES database, we observed
that several different categories of diseases were enriched in
the global data set, the majority being related to ‘‘Cancer,’’
‘‘Nervous System Disorders,’’ or a combination thereof (Fig-
ure 2D; Table S4).
Classification of Genes into Different Cortical
Developmental Stages
We used fuzzy c-means clustering (Kumar and E Futschik, 2007)
to group genes with significant changes in temporal expression
into clusters based on similarity in their temporal expression
patterns (Figure S3). This analysis generated 64 clusters ranging
in size from 65 to 854 genes with an average of 220 genes per
cluster (Figure S3).
The clusters were then classified by developmental stage,
using five different categories: ‘‘Pluripotency’’ (PP), ‘‘Neural
Differentiation’’ (ND), ‘‘Cortical Specification’’ (CS), ‘‘Deep Layer
neuron generation’’ (DL), and ‘‘Upper Layer neuron generation’’
(UL). To establish these categories, we examined genes known
to be associated with each stage and used their expression pro-
files to help establish milestones along the differentiation time
course. Pluripotency genes such as POU5F1 (OCT4), NANOG,
NODAL, and TDGF1 were found to be expressed highest at
Day 0 and to decrease dramatically thereafter, as expected,
thus setting clusters with highest expression at Day 0 as the
PP stage. PAX6, a known early indicator of neural commitment,
begins to be expressed at Day 7 and Sox1, another early neural
marker, peaks at Day 7; hence, we set the start of the ND stage at
Day 7. EMX2, a master regulator of cortical development (Cec-
chi, 2002), peaks at Day 12, setting the start of the CS stage at
day 12. For the DL stage, we examined TBR1 expression, a layer
6marker (Hevner et al., 2001), and found it upregulated at day 26.
Additionally, a marker of layer 5 cortical projection neurons,
BCL11B (CTIP2), rises in expression at day 33. Thus, we defined
the start of DL neuron generation at day 26. For the UL stage, we
looked at the recently identified human upper layer markers
CACNA1E, PRSS12, and CARTPT (Zeng et al., 2012) and found
their expression rises at day 63 and continues throughout, thus
defining the start of the UL stage as Day 63.
Once we established the developmental stages, we grouped
all the clusters with positive slopes of a certain degree (including
peaks) during the ND thru UL stages. In the case of the PP stage,
we grouped the clusters showing a negative slope after day 0.
This was done using a heuristic algorithm based on the changing
slopes of gene expression, rationalizing that positive slopes
indicate a critical role at that point in the process. It is possible
that genes could play critical roles at more than one period of
corticogenesis; for example, some genes are expressed in
both precursor cells and postmitotic neurons, so clusters exhib-
iting multiple peaks were classified into multiple stages. To take
into account multiple stage membership, we generated aweighted average of clusters for each stage by first calculating
the number of stages each cluster belongs to. We then gave
less weight to those clusters belonging to more than one stage
and calculated a representative expression profile for each
developmental stage (Figure 3A).
We next examined the other genes and clusters associated
with each developmental stage. The PP stage (containing 24
clusters) was exemplified by cluster 31 (Figure S3) and included
not only the pluripotency genes already mentioned but also
genes known to be vital to the differentiation of other lineages,
such as SOX17. Clusters present in the ND stage include cluster
38 (Figure S3), which has the LHX2 a gene implicated in neural
differentiation (Hou et al., 2013), and cluster 13 (Figure S3), which
contains NPTX1, a gene that plays a role in neural induction
(Boles et al., 2014). In addition to the known CS gene EMX2,
clusters with peaks at this stage (e.g., cluster 56; Figure S3)
include MDGA1 and FGF8 (cluster 54; Figure S3), already impli-
cated in cortical specification (Takeuchi et al., 2007; Toyoda
et al., 2010).
Global Analysis of Each Stage of Corticogenesis
After classifying genes into a developmental stage, we function-
ally categorized them via a GO analysis using the GOseq
package (Figure 3B; Table S6). We identified enriched GO cate-
gories for each stage and then used cateGOrizer to count the
number of GO categories. As expected, we found ‘‘Nervous
System Development’’ categories to be a major component of
each stage, starting with ND (Figure 3B).
Using the DISEASES database (Frankild and Jensen, 2013),
we determined disease affiliations that are overrepresented in
the genes associated with each stage (Figure 3C; Table S7).
For display purposes, we grouped diseases into four categories:
‘‘Eye Diseases,’’ ‘‘Nervous System Diseases,’’ ‘‘Cancers,’’ and
‘‘Other Diseases.’’ As pluripotent stem cells are inherently tumor-
igenic due to their propensity for teratoma formation, it was not
surprising that the PP stage is enriched for several cancer types.
Interestingly, both the ND and DL stages showed negligible
disease enrichment. The majority of disease terms enriched in
the CS stage are related to the nervous system and include the
major category ‘‘Neurodegenerative Disease.’’ The UL stage
shows enrichment for the most disease terms, and genes asso-
ciated with diseases such as schizophrenia and autism are
enriched in this stage. Moreover, three of the four cancer terms
associated with the UL stage are cancers of the nervous system.
Finally, in examining the ‘‘Other Diseases’’ category, three of the
15 diseases have connections to cortical and nervous system
defects (Bardet-Biedl syndrome, sudden infant death syndrome,
and lipoidosis).
Changes in signaling pathways for each stage were revealed
using the SPIA package. The SPIA method performs two mea-
surements, the first utilizes expression data to determine if the
components of pathways, as curated in the KEGG pathway
database, are significantly overrepresented. The second mea-
surement determines how likely it is that the current condition
impacts the functioning of each pathway (activating or rendering
it inactive). Pathways were categorized into six groups:
‘‘Nervous System,’’ ‘‘Cell Processes,’’ ‘‘Canonical Signaling,’’
‘‘Immune and Infectious Disease,’’ ‘‘Cancer,’’ and ‘‘Other’’Neuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc. 55
Figure 3. Developmental Stage Analysis of Temporal Expression Profiles
(A) Individual clusters were assigned to cortical developmental stages, classified as ‘‘Pluripotency’’ (PP), ‘‘Neural Differentiation’’ (ND), ‘‘Cortical Specification’’
(CS), ‘‘Deep Layer neuron generation’’ (DL), and ‘‘Upper Layer neuron generation.’’ Plots for each stage are shown, with the time period of a stage illustrated by a
gray band.
(legend continued on next page)
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ways enriched in the ND through UL stages pertained to the
‘‘Nervous System’’ group, such as axon guidance and different
neurotransmitter pathways (Figure 3E). Together, these data
provide functional insight into genes expressed at the different
stages of cortical development.
Functional Classification of Gene Clusters
We next examined each individual cluster (Figure S3) using GO,
KEGG pathway, and DISEASES enrichment analysis, as
described above. Clusters 18 (166 genes) and 34 (143 genes)
showed the greatest number of enriched developmental cate-
gories, and both of these clusters were associated with the ND
and CS stages (Figure 4A; Table S9). In cluster 18 nearly half
(13/28) of the associated GO categories deal with nervous sys-
tem development, and cluster 34 had most categories dealing
with nervous system development (10/13), with over half of those
more specifically involved in central nervous system develop-
ment (6/10). Cluster 18 and 34 are similar in having an early
peak that drops to a sustained level of expression; however,
cluster 18 expression rises at a faster rate than cluster 34 at
the early peak. Intriguingly, the composition of these clusters is
quite different: cluster 18, which includes 166 genes (Figure S3),
contains 42 (25%) transcription factors, whereas cluster 34,
which includes 143 genes, contains 50 (35%) membrane pro-
teins and 22 (15%) secreted molecules, illustrating two very
different roles for these clusters in the process of corticogenesis.
Another interesting cluster in this analysis is cluster 56 (152
genes), which is associated with the ND, CS, and UL stages. It
has seven enriched categories, and all are involved in nervous
system development. It includes 26 lincRNAs, 18 genes with
transcription regulator activity, 21 secreted proteins, 39 trans-
membrane proteins, and assorted other genes. Of the 18 tran-
scription regulatory factors, only four have previously been
associated with cortical development, and it will be worthwhile
investigating whether the remaining 14 genes are novel regula-
tors of human corticogenesis.
SPIA pathway analysis highlighted a different set of clusters,
with 32 clusters showing enrichment in at least one pathway (Fig-
ure 4B; Table S10). Cluster 47 (280 genes), which is associated
with the PP and DL stages, was enriched for the greatest number
of pathways, with two related to the nervous system, two related
to cancer, and six related to the immune system. This cluster
shows high expression in the PP stage and a shallow peak during
DL formation, after which expression peters out, suggesting
reduced involvement in mature cortical function. Genes asso-
ciated with Huntington’s disease and Alzheimer’s disease
pathways were also enriched in this cluster, and interestingly,
these pathways are rated as inactive based on the specific genes
present in cluster.
Cluster 58 (243 genes) and cluster 39 (370 genes) are specif-
ically associated with the UL stage. For cluster 58, four of the(B) GO enrichment for each of the cortical developmental stages.
(C) Enrichment for disease terms for each of the cortical developmental stages.
(D) KEGG pathway enrichment for each of the cortical developmental stages.
(E) Selected nervous-system-related KEGG pathways highlighted and displayed
pathway is active or inhibited by genes in each stage. See also Tables S6, S7, asix enriched pathways are concerned with the nervous system.
Cluster 58 includes a significant number, 77 (31% of the cluster),
of lincRNAs, the second highest lincRNA complement of any
cluster. This cluster also includes 33 (14%) secreted factors
and 60 (25%) transmembrane proteins. Interestingly, the other
cluster specific to the UL stage, cluster 39 (370 genes), also
has most of its enriched pathways associated with the nervous
system (2 out of 3). Furthermore, the composition of the two
clusters is similar, although cluster 39 contains fewer (46, 12%)
lincRNAs. The combination of GO and KEGG analyses pre-
sented here provides functional insight into coordinated gene
sets at different stages of cortical development and highlights
several that would be worthwhile exploring further.
We next investigated the clusters for associations with disease
(Figure 4C; Table S11) as described above. Only 11 clusters
showed enrichment for genes involved in disease, of which
two clusters are notable due to the number of associated
disease terms. Cluster 31 (854 genes) is specifically associated
with the PP stage and shows an enrichment for 14 disease terms,
eight of which are cancer related. Many genes driving pluripo-
tency also have roles in carcinogenesis (Lee et al., 2013), so
this finding is consistent with pluripotent cell biology. In contrast,
when looking at cluster 39, which in the KEGG pathway analysis
is principally involved in nervous system pathways, only seven
disease terms were associated with the nervous system, while
21 of 43 enriched terms were associated with cancer. Cluster
39 also showed enrichments for genes associated with develop-
mental disorders that affect cortical function. For example, there
is an enrichment in autism-associated genes, including WNT2,
GABRG1, and C4B, and in schizophrenia-associated genes,
including HTR2A, TPH1, and ZNF804A (Frankild and Jensen,
2013), indicating a potential role for other genes in this cluster
in those diseases.
Alternatively Spliced Transcripts during Human
Corticogenesis
Alternative splicing is an essential step in regulating the function
of the majority of protein-coding genes, and studies have impli-
cated abnormal splicing in several medical disorders (Padgett,
2012). Using the DEXseq package (Anders et al., 2012), we iden-
tified genes with evidence of alternative splicing in the Cortecon
data set and then looked for disease associations (Table S12).
As shown earlier, 5,017 genes had differential splicing during
in vitro corticogenesis (Figure 2A), with an average of 2.2 exons
per gene changing expression during the differentiation time
course. We used this subset of spliced genes, associated with
stage and cluster, to look for enrichment of disease terms as
we did for the total gene sets described above. Interestingly, in
the PP and CS stages, the spliced gene subsets compared to
the total stage gene sets were enriched in disease terms related
to cancer (Figure 5A; Table S13). In concordance, cluster 31
showed an increase in the number of enriched disease termswith calculated z scores. Backgrounds of each graph in (E) and (F) indicate if a
nd S8.
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Figure 4. Individual Cluster-Based Analysis of Temporal Expression Profiles
(A) GO enrichment for each of the temporal expression profile-derived clusters. Black arrowheads with numbers indicate specific clusters.
(B) KEGG pathway enrichment for each of the temporal expression profile-derived clusters. Black arrowheads with numbers indicate specific clusters.
(C) Enrichment for diseases for each of the temporal expression profile-derived clusters. Black arrowheads leading into black lines with numbers indicate specific
clusters. Expression profiles of clusters highlighted in each analysis is shown below each legend. See also Tables S9, S10, and S11 and Figure S3.
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Figure 5. Splice Form Analysis Reveals Roles in Neural Diseases and Cancer
Identification of genes in the data set with significant temporal changes in alternative splice forms.
(A) Enrichment for diseases for genes with alternative splice forms for both cortical developmental stages (left panel) and temporal expression profile-derived
clusters (right panel).
(B) Verification of alternative splice forms of TGIF1 by qRT-PCR.
(C) Verification of alternative splice forms of MARK1 by qRT-PCR. See also Tables S12, S13, and S14.
All error bars are SD.
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Table 1. Selected Genes from Each Stage
Entrez Gene ID Gene Symbols Stage
Stage
Eigenvector
Stage
Betweenness Associated Disease Max/Min Max/Threshold
183 AGT CS 0.8515 0.0162 Diabetes mellitus 626.88 227.72
UL 0.8571 0.0400 Brain disease
185 AGTR1 CS 0.7993 0.0190 Diabetic retinopathy Inf 7.85
UL 0.7929 0.0067 Brain disease
1565 CYP2D6 ND 0.5859 0.4384 Alzheimer’s disease 6.79 9.46
1571 CYP2E1 ND 0.9465 0.1982 Parkinson’s disease 24.94 2.66
1636 ACE CS 1.0000 0.1935 Central nervous
system disease
102.35 62.99
DL 0.1008 0.1516 Migraine
UL 1.0000 0.2366 Alzheimer’s disease
1813 DRD2 ND 0.5572 0.8659 Schizophrenia 22.87 56.87
1815 DRD4 ND 0.4424 0.0204 Autism 68.99 1605.65
2153 F5 UL 0.5776 0.0877 Migraine 274.48 66.40
2944 GSTM1 ND 1.0000 0.9109 Carcinoma 2.50 572.52
2947 GSTM3 ND 0.5304 0.0301 Childhood brain tumor 26.81 537.75
3106 HLA-B DL 0.6227 0.0385 Neurodegenerative disease 4.84 143.83
3113 HLA-DPA1 DL 0.0840 0.0016 Amyloidosis 4.28 10.11
3119 HLA-DQB1 DL 0.9222 0.0000 Pilocytic astrocytoma 7.30 157.24
3123 HLA-DRB1 DL 1.0000 0.0590 NA 7.24 45.24
3383 ICAM1 DS 0.3573 0.1023 Blindness 27.60 1451.80
3552 IL1A DL 0.1026 0.0358 Alzheimer’s disease 15.28 98.80
3553 IL1B CS 0.6087 0.5317 Alzheimer’s disease Inf 8.02
DL 0.1223 0.4333 Schizophrenia
3557 IL1RN UL 0.3693 0.0141 Brain disease Inf 1.14
3569 IL6 UL 0.6628 1.0000 Alzheimer’s disease Inf 34.19
3576 IL8 CS 0.4216 0.1884 Brain neoplasm Inf 71.94
3990 LIPC ND 0.4340 0.0592 Age-related macular
degeneration
Inf 4.47
4023 LPL ND 0.4934 0.8059 Cancer 44.81 1630.98
4524 MTHFR CS 0.6716 1.0000 Down syndrome 6.06 226.72
DL 0.0938 0.8549 Alzheimer’s disease
UL 0.7463 0.8106 Schizophrenia
4846 NOS3 CS 0.6416 0.2358 Alzheimer’s disease 4.95 62.27
4968 OGG1 ND 0.6267 0.0546 Neurodegenerative disease 3.52 291.74
5468 PPARG UL 0.3666 0.3778 Alzheimer’s disease 8.73 9.48
5683 PSMA2 PP 0.9990 0.0016 Alveolar echinococcosis 3.90 727.40
5684 PSMA3 PP 0.9995 0.0104 Chronic fatigue syndrome 5.05 5225.13
5685 PSMA4 PP 0.9904 0.0090 Keratoconus 3.87 2397.07
5687 PSMA6 PP 1.0000 0.0098 Heart disease 2.93 1216.66
5688 PSMA7 PP 0.9977 0.0067 Cancer 3.67 12907.39
5689 PSMB1 PP 0.9819 0.0014 Visceral leishmaniasis 2.67 2730.82
5690 PSMB2 PP 0.9845 0.0008 NA 2.95 693.59
5692 PSMB4 PP 0.9819 0.0026 Neurotic depression 2.19 7890.62
5693 PSMB5 PP 0.9857 0.0002 Multiple myeloma 2.51 6924.69
5701 PSMC2 PP 0.9897 0.0193 NA 2.35 1190.04
7040 TGFB1 CS 0.5385 0.4873 Holoprosencephaly 12.40 983.38
DL 0.0780 0.2332 Alzheimer’s disease
UL 0.5636 0.4556 Glioma
(Continued on next page)
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Table 1. Continued
Entrez Gene ID Gene Symbols Stage
Stage
Eigenvector
Stage
Betweenness Associated Disease Max/Min Max/Threshold
7422 VEGFA CS 0.4208 0.5852 Astrocytoma 5.82 401.39
UL 0.3529 0.3714 Neuroblastoma
7515 XRCC1 ND 0.8439 0.9213 Carcinoma 2.39 1766.83
100507436 MICA DL 0.0987 0.0137 Carcinoma 6.47 121.50
Shown are the top ten genes from each stage according to eigenvector centrality scores as derived from the network analysis. The fold change for each
gene from its peak to its trough in the time course is shown in the Max/Min column. TheMax/Threshold column shows change between the calculated
threshold for each gene and themax value. The remaining columns show the eigenvector centrality scores (EV) of the gene and betweenness centrality
score for its stage. Betweenness scores were normalized against the top betweenness score in its stage so that a score of 1 represents the highest
betweenness score.
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spliced, and a higher percentage of the terms are cancer related
in the spliced genes (91% versus 57%) (Figure 5A; Table S14). Of
the genes spliced differently over time, a number were associ-
ated with cortical-associated diseases.
To confirm alternative splicing at different stages, we carried
out qRT-PCR targeting specific splice forms for select examples.
We chose to examine TGFB-induced factor homeobox 1 (TGIF1;
cluster 14) due to its association with holoprosencephaly
(El-Jaick et al., 2007). We designed probes spanning exon junc-
tions with one probe belonging to nearly all splice forms of TGIF1
to act as a control and two spanning exon junctions of selected
TGIF1 isoforms and performed qRT-PCR. The expression values
were plotted as a percent expression of the control probe. One
exon junction demonstrated expression specifically at days 12
and 19 of differentiation (CS stage), while no expression was de-
tected at any of the other time points (Figure 5B, ‘‘purple’’). This
junction is associated with three splice forms of TGIF1, one of
which (splice form 4a) is the predominant TGIF1 splice form ex-
pressed in a range of human tissues, including brain (Hamid
et al., 2008). Thus, the expression of this exon junction specif-
ically during cortical specification, with low expression at later
times, may indicate a need for one of these three splice forms
during cortical patterning. One might speculate that as holopro-
sencephly occurs early in nervous system development, these
splice forms may be specifically involved in that pathology. The
other exon junction tested was unique to a specific TGIF1 splice
forms (Figure 5B, ‘‘blue’’), and it demonstrated changing expres-
sion throughout the time course, with expression being lowest
during PP but increasing throughout the remainder of cortico-
genesis (Figure 5B), suggesting a wider role during the process.
Together, these data demonstrate specific isoforms of TGIF1 are
expressed at specific times during cortical development, so that
defects in the splicing events at these times could contribute to
developmental disorders.
We next examinedMAP/microtubule affinity-regulating kinase
1 (MARK1) due to its implication in autism spectrum disorder
(ASD) (Maussion et al., 2008). We used four probes spanning
exon junctions: one spanning all to serve as a control, a second
to test a shortMARK1 splice forms, and a third and fourth probe
that split the remaining variants into two groups (Figure 5C). At
the start of the differentiation process, variant 1, the short splice
forms, makes up approximately 35% of the total MARK1 mes-
sage, increases to approximately 60% on day 7, reduces to35% at day 12–19 (Figure 5C), and thereafter steadily decreases
to 25% by day 77. Other probes indicate an increase in the
proportion of variant 4 splice forms as corticogenesis pro-
gresses, while splice forms 2 and 3 maintain a similar proportion
throughout. This suggests the short MARK1 splice forms
(variant 1) might play a critical role during early neural develop-
ment and cortical specification, while theMARK1 variant 4 splice
formsmight play a greater role at later stages of cortical develop-
ment. It will be interesting to explore these different splice forms
to determine if one in particular is critical for the progression of
autism-related pathologies.
Network Analysis Shows Autism-Related Genes in the
Context of Cortical Developmental
As development proceeds, waves of gene expressionmust work
coordinately to establish a fluid, systematic, neural progenitor
expansion and differentiation process. To further demonstrate
the utility of this data set and to obtain a greater understanding
of how genes in each cluster and stage relate to each other
throughout cortical development, we created a network based
on cocitations (see Supplemental Experimental Procedures,
available for download from http://cortecon.neuralsci.org/).
The resulting network was then filtered against lists of genes
belonging to a particular cluster or stage to obtain subgraphs.
Graph theoretic measures of ‘‘centrality’’ were then utilized to
find important nodes (genes) based on the relationships defined
within the structure of these subgraphs.
Using the igraph package (Csardi and Nepusz, 2006), we
utilized two methods for computing centrality, one more quanti-
tative (eigenvector centrality) and one more heuristic (between-
ness centrality) to determine genes pivotal to each cluster and
stage (Tables 1, S15 and S16). Utilizing these two distinct mea-
sures of centrality, we provide insight into the key players for
each cluster and developmental stage. To illustrate this method
of examining the data, we chose to focus on genes associated
with ASD from the DISEASES database (Frankild and Jensen,
2013) that change significantly in our data set. ASD encom-
passes a range of neurodevelopmental disorders, characterized
by social and communication deficits and repetitive behaviors
(Halfon and Kuo, 2013). We created a subgraph comprising
only those 171 genes related to ASD that change significantly
over the time course of in vitro corticogenesis (Table S17). After
constructing this subgraph, the genes in the graph were then
grouped by stage to visualize a potential ordering of geneNeuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc. 61
Figure 6. Literature-Based Network Analysis for ASD-Associated Genes in Data set
(A) Cocitation network for ASD-associated genes (DISEASES database) with significant temporal expression in RNA-seq data set. Larger nodes representing
genes of more importance to the network by betweeness centrality. Network is set up according to the cortical developmental stages: ‘‘Pluripotency’’ (PP; green),
‘‘Neural Differentiation’’ (ND; orange), ‘‘Cortical Specification’’ (CS; purple), ‘‘Deep Layer neuron generation’’ (DL; red), ‘‘Upper Layer neuron generation’’ (UL;
blue), and ‘‘multi-stage’’ (‘‘linked’’: yellow).
(legend continued on next page)
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a single stage (PP, ND, CS, DL, and UL) are each arranged in five
groups with a sixth group comprised of genes associated with
multiple stages (Figures 6A and 6B). Distributed around the cen-
tral group are groups of genes unique to a single stage, arranged
in a counter-clockwise fashion with the ‘‘Pluripotency stage’’ at
10 o’clock and each following stage thereafter. Genes that
have high centrality are highlighted in the network (Figure 6C).
This schematic (Figures 6A and 6B) gives an overall impression
of (a) the activity of genes over time (according to the stages),
(b) the importance of genes according to their measure of cen-
trality, and (c) the relationships/connections between genes
associated with autism.
A general impression of the developmental autism network is
that a myriad of receptors and ligands are at the center of each
stage (Figure 6). The gene with the highest eigenvector score is
catechol-O-methyltransferase (COMT), one of several enzymes
that degrade catecholamines such as dopamine, epinephrine,
and norepinephrine. Dopamine degradation by COMT is of
particular importance to the functions of the prefrontal cortex,
a region that our differentiation protocol enriches for (Figure 1E),
and polymorphisms in COMT affect working memory (Matsu-
moto et al., 2003). A serotonin receptor, HTR2C, has the highest
betweenness score in the network. Dysfunction in serotonin
signaling has been linked to autism (Scott and Deneris, 2005),
and several members of the serotonin receptor-family in addition
to HTR2C are also prominent at different cortical developmental
stages in the network: ‘‘PP’’ (green), HTR3A, HTR1A, and HTR7
and ‘‘UL’’ (blue), HTR5A, and HTR2A. HTR2A, in addition to
having the fourth highest eigenvector score in this network, is
also in the top 1% of eigenvector scores in the UL stage and
has the highest eigenvector score for cluster 39. Previous
studies have shown serotonin plays a role in cortical develop-
ment, and loss of serotonin results in abnormal development of
neurons in cortical layers 3 and 5 in rats (Vitalis et al., 2007).
Our data supports these studies and lends further credence to
the importance of serotonergic signaling during cortical develop-
ment and in ASD. Thus, the use of these networks can highlight
the interconnectivity of genes changing during the different
stages of cortical development and provide insight into which
stages might be most important for a specific disease, such as
ASD. By using the data provided in this resource, similar net-
works can be created for other diseases to highlight disease
associated processes.
Resource Utilization
To enhance the utility of this resource, we present the data and
analytical results in a searchable, web-based resource (http://
cortecon.neuralsci.org). Users can search for and navigate
genes, clusters, diseases, pathways, and ontology categories
of interest. The Cortecon resource provides a valuable standard
for comparison of other data sets. While the protocol described
here can robustly generate human cortical cells, culture varia-(B) ASD-associated gene network for ‘‘Upper Layers’’ (UL) stage highlighted.
(C) Table with genes that display highest Eigenvector centralities and Betweenne
Eigenvector and Betweenness values for the genes within overall cortical deve
Figure S5.tions exist from lab-to-lab, with two common variables being
(1) the variability of pluripotent stem cell (iPSC and hESC) lines
and (2) the starting cell density of the pluripotent stem cells. As
an example, when cortical differentiation was performed using
the same hESC line but with a lower cell density (approximately
60% compared to 85%) at the initiation of neural differentiation,
changes were observed in the resultant time course of cortico-
genesis, based upon the expression profile (Figure 7). The cells
were cultured for the full span of 77 days, with RNA sampled
at the same time points described in Figure 1 for RNA-seq.
Using Spearman rank correlations (Figures 7A and 7B), we
compared the original Cortecon data set to the lower density
test run data set and saw strong correlations at day 0 and day
7 between the two runs; however, correlations decreased at later
time points (Figure 7A). In order to assess whether the rate of
differentiation was different, we used the top 1,000 changing
genes in the Cortecon data as landmarks for the temporal
progression of corticogenesis (Figure 7B). Based upon these
landmarks, the test run differentiation was accelerated
throughout the early time course compared to the Cortecon
data set (i.e., day 33 of the test run showed strong correlations
with day 33–63 of the Cortecon data). We next examined the
overlap of significantly changing genes (Figure 7C) and found
that approximately 70% of the Cortecon genes were changed
in the test case. After examining the enriched GO Biological Pro-
cesses categories from both data sets, we found a high overlap
between each differentiation (Figure 7D). Finally, we compared
the percentage of deep and upper layer markers present in
each data set and noticed that while decreased compared to
the Cortecon data set, the test protocol did robustly generate
cortical neurons (Figure 7E). Importantly, we were able to
demonstrate that by using simple correlation analyses, re-
searchers can perform a temporal alignment of their data to
this reference set for corticogenesis, regardless of cell density.
We also compared the Cortecon data set to a similar data set
generated from mouse embryonic stem cells (Hubbard et al.,
2013) (Figure S4). Using the human/mouse homologs, the Pear-
son product-moment correlation coefficient (Pearson’s r) was
calculated between the time points of each data set. Within
each data set, adjacent time points were highly correlated, while
overall there was low correlation between the mouse and human
data, although the earlier time points were more correlated (Fig-
ure S4A). We next examined the expression of select genes
involved in neural differentiation and corticogenesis. Normalized
counts for each gene were scaled to the average expression of
the gene over the time course for each data set to facilitate the
comparison of expression profiles (Figure S4B). FOXG1 nearly
has identical profiles in mice and human corticogenesis, and
PAX6 and EMX2 have very similar profiles. Finally, GAD1 and
GRIK4 trend the same in both mouse and human, but their pro-
files are different (Figure S4B). Thus, ‘‘Cortecon’’ is a valuable
tool for researchers to identify similarities or differences even
across species over the differentiation time course.ss centralities within specific developmental stages of the ASD-gene network.
lopmental stages are given as well. See also Tables S15, S16, and S17 and
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Figure 7. Comparison of Cortecon Data Set to a Modified Cortical Protocol
A separate cortical differentiation was carried out with the starting cells at a reduced confluency of 60%–80% (test case).
(A and B) Spearman’s correlation was used to compare the Cortecon data and the test case. Heatmaps of the Spearman’s rho values describing the correlation
between every sample in the data set (A) using all genes and (B) using the top 1,000 significantly changing genes (the test case sample labels are indicated by a
gray background).
(C) A Venn diagram showing the overlap of significantly changing genes between the test case and the Cortecon data.
(D) A Venn diagram showing the overlap of GO categories between the test case and the Cortecon data.
(E) Percentage of layer markers (Zeng et al., 2012) expressed during the time course in the Cortecon data versus the test case. See also Figure S4.
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Until recently, insights into the molecular determinants of human
corticogenesis have primarily been inferred from non-human64 Neuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc.model systems. Since the first studies describing the differentia-
tion of hESCs into characteristic cortical neurons (Johnson et al.,
2007; Kim et al., 2011; Shi et al., 2012), this system is gaining
recognition as a valuable ‘‘development-in-a-dish’’ model of
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Transcriptome Analysis of Cortical Developmenthuman corticogenesis. Here, we describe a resource ‘‘Corte-
con’’ that we have created to help researchers exploring this
topic by cataloguing how the transcriptome changes during
human in vitro corticogenesis using RNA-seq technology,
demonstrating a variety of downstream analyses to show its util-
ity and value, and creating an online, readily searchable website
to access the resource.
Through a comparison to BrainSpan RNA-seq data sets, the
cortical neurons generated using this protocol were found to
be most closely associated with prefrontal cortical regions.
This is an important area to model in vitro, given its association
with a number of significant diseases and disorders, including
schizophrenia (Pomarol-Clotet et al., 2010), autism (Courchesne
et al., 2011), and age-related impairment in memory consolida-
tion and retrieval (Mander et al., 2013). While strongly suggestive
of a prefrontal cortical identity, this area takes longer to mature
than others such as somatosensory or visual cortical areas
(Gogtay et al., 2004). Thus, the high correlation to MFC could
also be attributed to the late persistence of genes associated
with cortical development, which will be interesting to explore
further.
Using the Cortecon data set, we can assess mechanisms of
cortical development established in other model systems for
their role in human. The radial glial marker NES was expressed
throughout the period of progenitor cell generation, as expected
(Figure S2). In general, neurons are born in order (Shen et al.,
2006), as they are in other species, confirming results in humans.
For example, Reelin is a marker of early born Cajal-Retsius cells
and is an important secreted molecule that guides organization
of the mouse cortex (Rice and Curran, 2001). In the Cortecon
data set, its expression increases early in the time course,
consistent with early-born Cajal-Retsius cell production. Inter-
estingly, this is followed by a much larger increase during the
UL stage, consistent with reports in the mouse of a later period
of generation of Reelin+ cortical cells (Fo¨rster et al., 2010). After
neurogenesis, gliogenesis occurs, and consistent with this, the
astrocyte marker GFAP greatly increases at the last time point
sampled (Figure S2).
FGF and WNT signaling play key roles in mouse corti-
cogenesis, and several of the related genes show similar trends
in expression in the Cortecon database to those reported in
mouse. For example, FGF8 plays a crucial role in mouse cortical
areal patterning (Toyoda et al., 2010) and in generating deep
layer neurons (Chalmers et al., 2002). In the Cortecon data set,
FG8 expression increases throughout the CS and DL stages
supporting a possible involvement during these early stages of
human corticogenesis. The FGF receptors (FGFR1, FGFR2,
and FGFR3) have been demonstrated to be essential for corti-
cogenesis (Rash et al., 2011), and their expression peaks during
the early stages of cortical development (Figure S2). Finally,
FGF10, which in mouse controls the differentiation of neuro-
epithelial cells into radial glia, has very low expression until upper
layer neurons are being generated (Sahara and O’Leary, 2009),
indicating a different role for FGF10 in human cortical
development.
To assess how the WNT pathway components changed, we
looked for WNT regulators in the Cortecon data set. WNT7B
and WNT8B play key roles in cortex formation in mouse, (Gardaet al., 2002), and in the Cortecon data set, their expression
increased during cortical specification (Figure S2). In addition
to pathway stimulation, WNT antagonism plays a critical role in
cortical development; for example, the WNT antagonist DKK1
impacts the early decision for neurectoderm to adopt a telence-
phalic fate (del Barco Barrantes et al., 2003). Using the Cortecon
data set, we assessed the expression profile of two WNT antag-
onists, DKK1 and FRZB. DKK1 sharply increased during the ND
stage, sharply decreased during the CS stage, and peaked again
at the UL stage. FRZB showed a similar pattern; however, it had
a much greater peak during the UL stage and a much smaller
peak during the ND stage (Figure S2).
Exploration of the Cortecon data set from different perspec-
tives will allow researchers to examine hypotheses centered
on human cortical development. One of the most interesting dis-
coveries made during this analysis was the catalog of alterna-
tively spliced transcripts present at different stages of cortical
development. Interestingly, the splice forms gene sets can
consolidate the disease enrichment of a gene cluster into
more narrow categories. For example, cluster 31, which fits
the pluripotency PP expression profile, had roughly 60% of
enriched diseases associated with cancer when looking at all
significantly changing genes. However, when focusing on genes
demonstrating alternative splicing, the disease enrichment was
now almost exclusively cancer related (Figures 3, 4, and 5).
These findings are in line with recent evidence showing overlap-
ping mechanisms underlying stem cell reprogramming and
tumorigenesis (Bernhardt et al., 2012), indicating that the differ-
entially expressed splice forms in cluster 31 not currently asso-
ciated with cancer are potential oncogenic candidates for
further study. In relation to cortical development, we identified
different isoforms expressed at different stages of in vitro
corticogenesis for TGIF1, which is associated with holoprosen-
cephaly (El-Jaick et al., 2007), and MARK1, which has been
implicated in ASD (Maussion et al., 2008) (Figure 5). These
data suggest that specific splice forms might be more relevant
to certain diseases based on the time they are expressed in
the developmental program. For example, three splice forms
of TGIF1 were expressed specifically at the early stages of
cortical development as the cortical field was being specified.
It could be that these transcripts are the ones critical for cortical
development, and subsequently the progression of holoprosen-
cepahly. Hence, the Cortecon resource will be valuable for those
interested in splicing mechanisms and how they contribute to
development, to changes in specific gene expressions, and to
a variety of neurological diseases.
Researchers can also use this resource to gain insight into
developmental pathways by applying network analysis strate-
gies. For example, the developmental autism network created
revealed that receptors and ligands associated with ASD are
key players at all stages of cortical development. Most notable
are genes related to serotonin signaling and GABAergic
signaling. Serotonin has been previously shown to be critical in
cortical development (Janusonis et al., 2004) and in autism
(Anderson et al., 2009; Janusonis et al., 2004). The ASD network
constructed using these data shows various serotonin receptors
as well as a serotonin-pathway-related enzymes to be important
at the PP and UL stages (Figure 6). Interestingly, one hypothesisNeuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc. 65
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of upper cortical layers 2–4, in which perturbed serotonin
signaling results in altered layer formation, possibly contributing
to ASD pathology (Altamura et al., 2007). In addition, the autism
network indicates several GABA-receptors are involved in
different stages of in vitro corticogenesis, with individual
subtypes showing distinct temporal expression patterns (Fig-
ure 6). Many genes encoding presynaptic and postsynaptic
proteins located at GABAergic synapses have been implicated
in autism pathology (Delorme et al., 2013), and as indicated by
our data set, many of these genes also appear to play a role in
corticogenesis.
Application of this network approach enables different
clusters to be connected to each other, allowing interrogation
of interactions between clusters. For example, genes in cluster
18, which shows an early peak and is largely composed of tran-
scriptional regulators, may regulate the expression of genes in
cluster 34, which also shows an early peak but is principally
composed of signaling molecules. To test this hypothesis, we
examined a network composed of both clusters and observed
the transcription factors in cluster 18 were highly connected
with the signaling molecules in cluster 34 (Figure S5). In fact, in
a network constructed from the genes in cluster 34 and the
transcription factors from cluster 18, we found that a cluster 18
transcription factor (SOX5) had the highest betweenness and
closeness centrality scores in the network, and this corroborates
the critical role of Sox5 in mouse cortical development (Lai et al.,
2008). Moreover, SOX5 is directly linked to Myocyte Enhancer
Factor 2C (MEF2C), which is a transcription factor belonging to
cluster 34 and has the second highest betweenness and
closeness centrality scores in this network. Other cluster 18
transcription factors are similarly linked to cluster 34 genes.
This underscores the potential importance of cluster 18 in the
correct expression of genes in cluster 34. Using this network
approach to search for temporally relevant regulators of each
cluster can provide insight into how each cluster is connected
and regulated and focus attention on particular pathways to un-
cover mechanisms underlying human cortical development in
health and disease.
EXPERIMENTAL PROCEDURES
Human ESC Differentiation
Human ESCs (WA-09,WiCell) weremaintained on irradiatedmouse embryonic
fibroblasts (GobalStem) according to standard culture procedures. In some
cases, hESCS were maintained using StemBeads FGF2 (StemCulture). Induc-
tion of neural progenitors was initiated using an adaptation of the dual SMAD-
inhibition protocol (Chambers et al., 2009). Cyclopamine was added from day
3 of neural induction to ensure an anterior cortical fate (Gaspard et al., 2008).
Throughout the entire subsequent cortical differentiation, cultures were main-
tained in N2B27-medium (Gaspard et al., 2008) supplemented with 10 ng/ml
FGF-2. See Supplemental Experimental Procedures.
Quantitative RT-PCR
Quantitative RT-PCR was performed using TaqMan gene expression assays
(Life Technologies); see Supplemental Experimental Procedures.
Immunocytochemistry
Immunocytochemistry was carried out using standard procedures; see
Supplemental Experimental Procedures.66 Neuron 83, 51–68, July 2, 2014 ª2014 Elsevier Inc.RNA-Seq Application
Samples were collected using RNAprotect cell reagent (QIAGEN), and total
RNA was extracted using RNeasy plus mini kit (QIAGEN), according to the
manufacturer’s protocol. RNA samples were subject to RNA-seq by Expres-
sion Analysis (Durham) or Covance (Seattle): TruSeq RNA sample prep kit
(v2), HiSeq2000 platform (Illumina), paired-end, 50 cycles, multiplex (EA
4-plex; Covance 5-plex).
RNA-Seq Data Analysis
FASTQ files were mapped to the hg19 assembly via BFAST (Homer et al.,
2009) and analyzed using R (Team, 2012), an open source programming envi-
ronment for statistical computing and graphics, and a variety of packages
available through Bioconductor (Gentleman et al., 2004), an open develop-
ment project. FastQC was used to assess the quality of the sequencing (Table
S18). All code and R sessions are provided for download from http://cortecon.
neuralsci.org/. Files can also be downloaded from GEO: GSE56796. See Sup-
plemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, eighteen tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.05.013.
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